All In Biotech

Drug Trial Radar · NCT06613633

Third-generation EGFR-TKI Treatment in Metastatic EGFR-mutant NSCLC

Pattern of Failure and Feasibility of Consolidative Stereotactic Radiotherapy in Third-generation EGFR-TKI-treated Metastatic EGFR-mutant Non-small Cell Lung Cancer: A Prospective, Observational Study

Last checked: Nov 19, 2026Latest source record: Apr 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

4,000

Actual

Start

Sep 1, 2018

Primary completion

Aug 1, 2024

Study completion Feb 20, 2026

Sponsor

Lead sponsor
Fudan UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Shanghai Chest Hospital; Wuhan TongJi Hospital
First posted
Sep 26, 2024

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this observational study is to explore the feasibility of stereotactic radiotherapy (SRT) as consolidation therapy for patients with advanced non-small-cell lung cancer who were treated with third-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI). The investigators plan to explore the time to achieve the best response after EGFR-TKI treatment, the characteristics of the distribution of lesions when the best response is achieved, the feasibility of SRT when the best response is achieved, and the phenotype of disease progression after EGFR-TKI resistance. In summary, this study will provide critical information for exploring the feasibility and optimal design of SRT as consolidation therapy for advanced NSCLC patients treated with third-generation EGFR-TKI, which will further promote the optimization of comprehensive treatment for EGFR-mutant advanced NSCLC.

Conditions

  • Third-generation TKI
  • NSCLC (Advanced Non-small Cell Lung Cancer)

Interventions

  • third-generation EGFR-TKI (Osimertinib, Almonertinib or Furmonertinib)Drug

    Patients with advanced EGFR-mutated NSCLC who met the inclusion criteria and received third-generation EGFR-TKI (monotherapy or combined with brain radiotherapy)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to Best ResponseTime frame: 5 years

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Wuhan Tongji Hospital

    Wuhan, Hubei, China

  • Shanghai Cancer Center

    Shanghai, Shanghai Municipality, China

  • Shanghai Chest Hospital

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.